Does MaineCare Cover Weight Loss Medication? GLP-1s and LD 480

MaineCare does not cover weight loss medication for adults. GLP-1 drugs such as Ozempic, Wegovy, and Zepbound are paid for only when they are prescribed for Type 2 diabetes or a narrow set of cardiovascular conditions, not for obesity treatment on its own. A 2025 bill that would have changed this, LD 480, failed, and no federal law requires Maine to provide the coverage.¹

When MaineCare Will Pay for a GLP-1

The same molecules are FDA-approved for more than one condition, which is why coverage depends entirely on the diagnosis behind the prescription.

Rybelsus, the oral semaglutide approved for Type 2 diabetes, is a preferred drug on the MaineCare formulary and does not require prior authorization.²

Wegovy, the higher-dose semaglutide marketed for weight management, is listed as non-preferred and is covered only under strict criteria. A patient must have a BMI above 27 and a documented history of stroke, heart attack, or symptomatic peripheral arterial disease, and the drug cannot be used “for weight loss only.” Patients with diabetes, end-stage renal disease, or severe heart failure are excluded from Wegovy coverage altogether.² In practice, Wegovy clears only for cardiovascular risk reduction in a small subset of members. An adult who is obese but does not have one of the listed cardiovascular conditions cannot get any GLP-1 covered for the purpose of losing weight.³

Children are treated differently. MaineCare covers these medications for minors when deemed medically necessary under the federal Early and Periodic Screening, Diagnostic and Treatment benefit, which gives children broader access to treatments than adults receive.¹

What MaineCare Does Cover for Obesity

MaineCare pays for bariatric surgery with prior authorization. Eligible procedures include gastric bypass, gastric banding, and sleeve gastrectomy. Candidates generally need a BMI of 40 or higher, or a BMI of 35 with a complication such as diabetes, heart disease, high blood pressure, or sleep apnea. The surgery must be medically necessary to address a related health condition, and the prior authorization request must come from the surgeon performing the procedure.⁴⁵ Adolescent patients face additional requirements, including recommendations from a primary care provider and a licensed mental health provider specializing in children’s mental health.⁶

MaineCare also covers preventive counseling, annual physicals, and medical nutritional therapy for members with obesity. Health club memberships are explicitly excluded.⁴

Why the Legislature Said No in 2025

Representative Anne Graham of North Yarmouth introduced LD 480, “An Act to Support Healthy Weight by Providing MaineCare Coverage for Certain Weight Loss Medications,” in early 2025. The bill would have required MaineCare to reimburse for FDA-approved GLP-1 receptor agonists prescribed for obesity by a primary care provider or bariatric specialist, subject to prior authorization.⁷

The Maine Medical Association and the Maine Osteopathic Association supported the bill, arguing coverage would reduce long-term costs by preventing obesity-related chronic disease.⁸ Dr. Allen Browne testified that it was “wrong” to tell patients a safe and effective treatment exists but withhold it over cost, and said some providers avoid mentioning the drugs at all because they know insurance will not pay.¹

The Mills administration opposed the bill. MaineCare’s medical director, Courtney Pladsen, called the cost “prohibitive” and “untenable,” citing a $118 million MaineCare shortfall. The Department of Health and Human Services estimated coverage would cost $42 million in 2026 and $53 million in 2027, with a 30-day supply running between $1,000 and $1,500.¹ The Health and Human Services Committee voted “Ought Not to Pass” on March 11, 2025, and the Senate placed the bill in legislative files on March 20.⁷

What Could Change Coverage Next

A separate bill in the 132nd Legislature, LD 627, introduced by Representative Holly Stover, would require insurance coverage for GLP-1 receptor agonist medications. It is categorized under “Insurance” and “Health Insurance” rather than specifically targeting MaineCare, and its status remains pending.⁹

At the federal level, no law requires state Medicaid programs to cover anti-obesity drugs. A Biden-era proposal that would have mandated coverage was not pursued by the Trump administration.¹⁰ In December 2025 the Trump administration launched the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) model through the CMS Innovation Center, a five-year voluntary program in which CMS negotiates lower GLP-1 prices with manufacturers for participating state Medicaid agencies and Medicare Part D plans. Covered drugs include all formulations of Mounjaro, Ozempic, Rybelsus, and Wegovy, the KwikPen formulation of Zepbound, and potentially orforglipron if it gains FDA approval.¹¹

States can begin participating as early as May 2026, with applications due July 31, 2026, and implementation rolling out through January 2027. Participation is voluntary, and the model does not guarantee coverage for any individual patient; BMI and clinical thresholds and prior authorization will still apply. The negotiated Medicaid price under BALANCE is confidential, though the Medicare net price has been set at $245 per month.¹²

Whether Maine will apply remains unknown. There is no public record of Maine submitting an application or stating an intent to participate, and given the fiscal arguments the Mills administration raised against LD 480, joining would be a significant shift. The Maine Prescription Drug Affordability Board has discussed GLP-1 costs and other states’ coverage decisions but has not issued formal recommendations.¹³

1
Portland Press Herald. Maine Lawmaker Wants MaineCare to Cover Ozempic and Other Weight Loss Drugs
2
MaineCare PDL. MaineCare PDL Changes Effective January 1, 2025
3
GLP1 Clinics. MaineCare GLP-1 Coverage in Maine
4
GWU STOP. Medicaid Obesity Coverage – Maine
5
NEWS CENTER Maine. Weight Loss Surgery: Is It for You
6
Maine.gov. Change in Criteria for Adolescent Bariatric Surgeries
7
Maine State Legislature. LD 480 – Bill Status
8
Maine State Legislature. LD 480 Testimony – Maine Medical Association and Maine Osteopathic Association
9
Maine Legislature. LD 627 – An Act to Require Insurance Coverage for GLP-1 Receptor Agonist Medication
10
KFF. Medicaid Coverage of and Spending on GLP-1s
11
CMS. BALANCE Model
12
KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid
13
Maine.gov. MPDAB Annual Report 2025